000147645 001__ 147645
000147645 005__ 20240229123025.0
000147645 0247_ $$2doi$$a10.1007/s00066-019-01540-8
000147645 0247_ $$2pmid$$apmid:31732784
000147645 0247_ $$2ISSN$$a0039-2073
000147645 0247_ $$2ISSN$$a0179-7158
000147645 0247_ $$2ISSN$$a1439-099X
000147645 0247_ $$2altmetric$$aaltmetric:70570031
000147645 037__ $$aDKFZ-2019-02636
000147645 041__ $$aeng
000147645 082__ $$a610
000147645 1001_ $$aGerum, Sabine$$b0
000147645 245__ $$aStereotactic body radiotherapy in patients with hepatocellular carcinoma in a multimodal treatment setting.
000147645 260__ $$aHeidelberg$$bSpringer Medizin$$c2020
000147645 3367_ $$2DRIVER$$aarticle
000147645 3367_ $$2DataCite$$aOutput Types/Journal article
000147645 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1601370836_28064
000147645 3367_ $$2BibTeX$$aARTICLE
000147645 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000147645 3367_ $$00$$2EndNote$$aJournal Article
000147645 500__ $$a2020 Apr;196(4):334-348#LA:E055#
000147645 520__ $$aRetrospective evaluation of stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma (HCC).We retrospectively analyzed 36 patients (45 lesions) treated between 2011 and 2017. Twenty-seven had previous treatments. Current treatment consisted of SBRT alone (n = 15) or selective transarterial chemoembolization (TACE) followed by SBRT to the same lesions (n = 21). Eight patients received additional local treatments to different lesions. Liver function was predominantly moderately restricted (Child A: 29, Child B: 6, Child C: 1). Treatment planning was based on 4D-computed tomography, dose/fractionation varied depending on location and size, most commonly 3 fractions of 12.5 Gy (65% isodose) and 5 fractions of 8 Gy (80% isodose).Median follow-up was 15 months. Local recurrence was observed in 3 lesions (7%), resulting in 1‑and 2‑year local control rates of 93%. The only significantly predicting factor was the use of abdominal compression. New hepatic lesions occurred in 19 patients (52%), 1‑ and 2‑year freedom-from-hepatic-failure (FFHF) was 39% and 32%, respectively. Only the number of treated lesions was predictive for FFHF. Sixteen patients have died, resulting in 1‑ and 2‑year overall survival (OS) of 64% and 41%, respectively, significantly impacted by the number of treated lesions and Child-Pugh class. Severe acute and late toxicity (≥grade 3) was observed in 3% and 8%, respectively. 6 patients (17%) received liver transplantation (OLT) after SBRT, of whom 5 showed pathological complete remission.SBRT (±TACE) in highly pretreated HCC is effective and associated with excellent LC and low toxicity. SBRT may be used as definitive or bridging treatment prior to OLT. Patients with multifocal lesions have significantly decreased 1‑ and 2‑year FFHF and OS.
000147645 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000147645 588__ $$aDataset connected to CrossRef, PubMed,
000147645 7001_ $$aHeinz, Christian$$b1
000147645 7001_ $$aBelka, Claus$$b2
000147645 7001_ $$aWalter, Franziska$$b3
000147645 7001_ $$aPaprottka, Philipp Marius$$b4
000147645 7001_ $$aDe Toni, Enrico N$$b5
000147645 7001_ $$00000-0003-3787-7386$$aRoeder, Falk$$b6$$eLast author
000147645 773__ $$0PERI:(DE-600)2003907-4$$a10.1007/s00066-019-01540-8$$n4$$p334-348$$tStrahlentherapie und Onkologie$$v196$$x1439-099X$$y2020
000147645 909CO $$ooai:inrepo02.dkfz.de:147645$$pVDB
000147645 9101_ $$0I:(DE-588b)2036810-0$$60000-0003-3787-7386$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000147645 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000147645 9141_ $$y2020
000147645 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000147645 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000147645 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000147645 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSTRAHLENTHER ONKOL : 2017
000147645 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000147645 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000147645 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000147645 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000147645 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000147645 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000147645 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000147645 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000147645 9202_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Translationale Radioonkologie$$x0
000147645 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Translationale Radioonkologie$$x0
000147645 980__ $$ajournal
000147645 980__ $$aVDB
000147645 980__ $$aI:(DE-He78)E055-20160331
000147645 980__ $$aUNRESTRICTED